Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Income: 2019-2025

Historic Net Income for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$32.2 million.

  • C4 Therapeutics' Net Income fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 12.88%. This contributed to the annual value of -$105.3 million for FY2024, which is 20.51% up from last year.
  • Per C4 Therapeutics' latest filing, its Net Income stood at -$32.2 million for Q3 2025, which was down 23.62% from -$26.0 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Net Income registered a high of -$15.7 million during Q4 2021, and its lowest value of -$35.9 million during Q2 2023.
  • Over the past 3 years, C4 Therapeutics' median Net Income value was -$28.4 million (recorded in 2024), while the average stood at -$29.3 million.
  • In the last 5 years, C4 Therapeutics' Net Income tumbled by 109.21% in 2021 and then surged by 50.68% in 2024.
  • Over the past 5 years, C4 Therapeutics' Net Income (Quarterly) stood at -$15.7 million in 2021, then tumbled by 75.07% to -$27.4 million in 2022, then dropped by 26.78% to -$34.8 million in 2023, then increased by 0.52% to -$34.6 million in 2024, then tumbled by 30.41% to -$32.2 million in 2025.
  • Its last three reported values are -$32.2 million in Q3 2025, -$26.0 million for Q2 2025, and -$26.3 million during Q1 2025.